Abstract

Mesenchymal stem cell (MSC)-sourced secretome, defined as the set of MSC-derived bioactive factors (soluble proteins, nucleic acids, lipids and extracellular vesicles), showed therapeutic effects similar to those observed after transplantation of MSCs. MSC-derived secretome may bypass many side effects of MSC-based therapy, including unwanted differentiation of engrafted MSCs. In contrast to MSCs which had to be expanded in culture to reach optimal cell number for transplantation, MSC-sourced secretome is immediately available for treatment of acute conditions, including fulminant hepatitis, cerebral ischemia and myocardial infarction. Additionally, MSC-derived secretome could be massively produced from commercially available cell lines avoiding invasive cell collection procedure. In this review article we emphasized molecular and cellular mechanisms that were responsible for beneficial effects of MSC-derived secretomes in the treatment of degenerative and inflammatory diseases of hepatobiliary, respiratory, musculoskeletal, gastrointestinal, cardiovascular and nervous system. Results obtained in a large number of studies suggested that administration of MSC-derived secretomes represents a new, cell-free therapeutic approach for attenuation of inflammatory and degenerative diseases. Therapeutic effects of MSC-sourced secretomes relied on their capacity to deliver genetic material, growth and immunomodulatory factors to the target cells enabling activation of anti-apoptotic and pro-survival pathways that resulted in tissue repair and regeneration.

Highlights

  • Many degenerative and inflammatory diseases are in the focus of stem cell-based research

  • In contrast to Mesenchymal stem cell (MSC) which had to be expanded in culture to reach optimal cell number for transplantation, MSC-sourced secretome is immediately available for treatment of acute conditions including fulminant hepatitis, cerebral ischemia and myocardial infarction [39]

  • Contains low levels of factors which promote tumor growth (epidermal growth factor receptor (EGFR), fibroblast growth factor (FGF)-4 and -9), neo-angiogenesis (VEGF, IL-6, IL6 receptor), homing of naïve T cells to peripheral lymph nodes (chemokine (C-C motif) ligand 7 (CCL7)) and migration of circulating monocytes in tumor tissue (macrophage migration inhibitory factor (MMIF)) [37]. These findings indicate that MSC-derived conditioned medium (MSC-conditioned medium (CM))-based effects depend on MSCs origin and suggest that content of MSC-CM should be precisely determined before clinical application

Read more

Summary

Introduction

Many degenerative and inflammatory diseases are in the focus of stem cell-based research. In this review article we summarized findings obtained in preclinical and clinical studies that delineated molecular and cellular mechanisms which were responsible for beneficial effects of MSC-derived secretomes in attenuation of degenerative and inflammatory diseases of hepatobiliary, respiratory, musculoskeletal, gastrointestinal, cardiovascular and nervous system. Various biological effects were observed in experimental animals after administration of MSC-CM and MSC-EVs. Importantly, MSC-sourced secretome bypassed many limitations of MSC-based therapy, including unwanted differentiation and potential activation of allogeneic immune response. MSC-sourced secretomes showed immunoregulatory, angiomodulatory and anti-apoptotic effects that resulted in enhanced tissue repair and regeneration [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41]

Immunomodulatory Properties of MSC-Derived Secretome
The Role of MSC-Sourced Secretome in Tissue Repair and Regeneration
MSC-Sourced Secretome in the Therapy of Lung Diseases
Findings
Therapeutic Potential of MSC-Derived Secretome in Cartilage Regeneration
Attenuation of Inflammatory Bowel Diseases by MSC-Derived Secretome
MSC-Sourced Secretome as an Emerging Tool for Myocardial Regeneration
Beneficial Effects of MSC-Derived Secretome in the Therapy of Eye Disease
Molecular mechanismsresponsible responsible for for beneficial
Clinical Studies Addressing Therapeutic Potential of MSC-Derived Secretome
ConclusionsThis and Future

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.